StockNews.AI
CAPR
StockNews.AI
29 days

Shareholders that lost money on Capricor Therapeutics, Inc.(CAPR) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

1. Class action notice issued for Capricor shareholders regarding misleading statements. 2. Investors were misled concerning deramiocel's FDA approval prospects. 3. CAPR stock price dropped significantly post FDA Complete Response Letter. 4. Class period covers October 9, 2024 to July 10, 2025. 5. Gross Law Firm seeks recovery for shareholders impacted by false information.

6m saved
Insight
Article

FAQ

Why Very Bearish?

The stock experienced a sharp drop after negative FDA news, indicating strong investor reactions. Historical cases suggest similar situations lead to continued declines in share prices following class action announcements.

How important is it?

The article discusses potential legal consequences for Capricor, which can lead to significant financial ramifications. High-profile class actions often attract media scrutiny and can influence future investor confidence.

Why Short Term?

The immediate negative sentiment following the FDA's CRL affects stock price in the short term. Previous incidents show investor confidence often takes time to recover from regulatory setbacks.

Related Companies

DMDBLA
, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR). Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/capricor-loss-submission-form/?id=157187&from=4 CLASS PERIOD: October 9, 2024 to July 10, 2025 ALLEGATIONS: According to the complaint, defendants provided investors with material information concerning Capricor's lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Defendants' statements included, among other things, Capricor's ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration (FDA). Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel.   On July 11, 2025, Capricor issued a press release announcing it received a Complete Response Letter (CRL) from the FDA denying the BLA specifically citing it did not meet the statutory requirement for substantial evidence of effectiveness and the need for additional clinical data. Further, the CRL referenced outstanding items in the Chemistry, Manufacturing, and Controls section of the application.   Following this news, the price of Capricor stock declined from $11.40 per share on July 10, 2025 to $7.64 per share on July 11, 2025. DEADLINE: September 15, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/capricor-loss-submission-form/?id=157187&from=4 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of CAPR during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is September 15, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: [email protected]Phone: (646) 453-8903 SOURCE The Gross Law Firm WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News